Literature DB >> 21605099

Haem arginate as effective maintenance therapy for hereditary coproporphyria.

Ellen Ma1, Victoria Mar, George Varigos, Amanda Nicoll, Gayle Ross.   

Abstract

A 35-year-old woman presented with skin fragility and photosensitivity with blisters affecting her face and hands. Other symptoms included intermittent headache, fatigue, abdominal pain and nausea. Porphyrin studies were markedly raised, with features consistent with hereditary coproporphyria (HCP). Despite strict precautions, symptoms remained significantly problematic. Regular haem arginate infusions of 3 mg/kg per day over 4 days on a monthly basis were commenced and resulted in significant improvement of the patient's symptoms and a reduction in urinary porphobilinogen. Although haem arginate infusion is known as a treatment for severe acute attacks of HCP, the effectiveness of regular infusions as maintenance therapy has not been established. This is the first report of effective symptom control correlating with normalization of biochemical markers in a patient receiving regular haem arginate infusions for the treatment of HCP.
© 2011 The Authors. Australasian Journal of Dermatology © 2011 The Australasian College of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21605099     DOI: 10.1111/j.1440-0960.2011.00747.x

Source DB:  PubMed          Journal:  Australas J Dermatol        ISSN: 0004-8380            Impact factor:   2.875


  3 in total

1.  Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms.

Authors:  Joanne T Marsden; Simon Guppy; Penelope Stein; Timothy M Cox; Michael Badminton; Tricia Gardiner; Julian H Barth; M Felicity Stewart; David C Rees
Journal:  JIMD Rep       Date:  2015-03-12

Review 2.  Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Authors:  Petro E Petrides
Journal:  Diagnostics (Basel)       Date:  2022-07-03

3.  Heme oxygenase, inflammation, and fibrosis: the good, the bad, and the ugly?

Authors:  Ditte M S Lundvig; Stephan Immenschuh; Frank A D T G Wagener
Journal:  Front Pharmacol       Date:  2012-05-07       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.